Sage Journals: Discover world-class research

Abstract

Background

In septic shock, vasopressors aim to improve tissue perfusion and prevent persistent organ dysfunction, a characteristic of chronic critical illness (CCI). Adjunctive vasopressin is often used to decrease catecholamine dosage, but the association of vasopressin response with subsequent patient outcomes is unclear. We hypothesized vasopressin response is associated with favorable clinical trajectory.

Methods

We included patients with septic shock receiving vasopressin as a catecholamine adjunct in this retrospective cohort study. We defined vasopressin response as a lowering of the catecholamine dose required to maintain mean arterial pressure ≥65 mm Hg, 6 h after vasopressin initiation. Clinical trajectories were adjudicated as early death (ED; death before day 14), CCI (ICU stay ≥14 days with persistent organ dysfunction), or rapid recovery (RR; not meeting ED or CCI criteria). Trajectories were placed on an ordinal scale with ED the worst outcome, CCI next, and RR the best outcome. The association of vasopressin response with clinical trajectory was assessed with multivariable ordinal logistic regression.

Results

In total 938 patients were included; 426 (45.4%) were vasopressin responders. The most frequent trajectory was ED (49.8%), 29.7% developed CCI, and 20.5% had rapid recovery. In survivors to ICU day 14 (those without ED), 59.2% had CCI and 40.8% experienced RR. Compared with vasopressin non-responders, vasopressin responders less frequently experienced ED (42.5% vs. 55.9%) and more frequently experienced RR (24.6% vs. 17.0%; P < 0.01). After controlling for confounders, vasopressin response was independently associated with higher odds of developing a better clinical trajectory (OR 1.63; 95% CI 1.26−2.10). Medical patients most frequently developed ED and survivors more commonly developed CCI than RR; surgical patients developed the three trajectories with similar frequency (P < 0.01).

Conclusions

Vasopressin responsive status was associated with improved clinical trajectory in septic shock patients. Early vasopressin response is a potential novel prognostic marker for short-term clinical trajectory.

Keywords

septic shock sepsis vasopressin vasoconstrictor agents clinical trajectory chronic critical illness

Get full access to this article

View all access options for this article.

References

Rhee

Dantes

Epstein

, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. JAMA. 2017;318(13):1241‐1249.

Liu

Escobar

Greene

, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA. 2014;312(1):90‐92.

Evans

Rhodes

Alhazzani

, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063‐e1143.

Maheshwari

Nathanson

Munson

, et al. The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med. 2018;44(6):857‐867.

Sacha

Kiser

Wright

, et al. Association between vasopressin rebranding and utilization in patients with septic shock. Crit Care Med. 2022;50(4):644‐654.

Sacha

Lam

Duggal

, et al. Predictors of response to fixed-dose vasopressin in adult patients with septic shock. Ann Intensive Care. 2018;8(1):35.

Stortz

Mira

Raymond

, et al. Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients. J Trauma Acute Care Surg. 2018;84(2):342‐349.

Gardner

Ghita

Wang

, et al. The development of chronic critical illness determines physical function, quality of life, and long-term survival among early survivors of sepsis in surgical ICUs. Crit Care Med. 2019;47(4):566‐573.

Brakenridge

Efron

Cox

, et al. Current epidemiology of surgical sepsis: discordance between inpatient mortality and 1-year outcomes. Ann Surg. 2019;270(3):502‐510.

10.

Hawkins

Raymond

Stortz

, et al. Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome. Front Immunol. 2018-July-02 2018;9:1511.

11.

Lederer

Bell

Branson

, et al. Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals. Ann Am Thorac Soc. 2019;16(1):22‐28.

12.

Harrell

. Ordinal Logistic Regression. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Springer International Publishing; 2015:311‐325.

13.

Colantuoni

Scharfstein

Wang

, et al. Statistical methods to compare functional outcomes in randomized controlled trials with high mortality. Br Med J. 2018;360:j5748.

14.

Stolk

van der Pasch

Naumann

, et al. Norepinephrine dysregulates the immune response and compromises host defense during sepsis. Am J Respir Crit Care Med. 2020;202(6):830‐842.

15.

Stortz

Murphy

Raymond

, et al. Evidence for persistent immune suppression in patients who develop chronic critical illness after sepsis. Shock. 2018;49(3):249‐258.

16.

Resche-Rigon

Azoulay

Chevret

. Evaluating mortality in intensive care units: contribution of competing risks analyses. Crit Care. 2006;10(1):R5.

17.

Khanna

English

Wang

, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419‐430.

18.

Allen

Kram

, et al. Predictors of vasopressin responsiveness in critically ill adults. Ann Pharmacother. 2018;52(2):126‐132.

19.

Bissell

Erdman

Smotherman

Kraemer

Ferreira

. The impact of endocrine supplementation on adverse events in septic shock. J Crit Care. 2015;30(6):1169‐1173.

20.

Dubrawka

Betthauser

Pope

Gibson

. Effect of vasopressin dose on hemodynamic response in obese patients with septic shock: a retrospective observational study. Ann Pharmacother. 2021;55(12):1447‐1454.

21.

Hammond

Cullen

Painter

, et al. Efficacy and safety of the early addition of vasopressin to norepinephrine in septic shock. J Intensive Care Med. 2019;34(11–12):910‐916.

22.

Sacha

Lam

Wang

Duggal

Reddy

Bauer

. Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock. Crit Care Med. 2022;50(4):614‐623.

23.

Scheibner

Betthauser

Bewley

, et al. Machine learning to predict vasopressin responsiveness in patients with septic shock. Pharmacotherapy. 2022;42(6):460‐471.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.96 MB

Vasopressin Response and Clinical Trajectory in Septic Shock Patients

Abstract

Background

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material